Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

The "Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Systemic Sclerosis (Scleroderma), Breast Cancer, Inflammation, Inflammatory Bowel Disease, Lung Cancer, Multiple Sclerosis, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Ischemic Stroke, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Osteoarthritis Pain, Ovarian Cancer, Pain, Solid Tumor, Thyroid Cancer and Visceral Pain.

The latest report Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
  • The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Overview
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development
  • Blade Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co
  • Galapagos NV
  • iOnctura SA
  • LegoChem Biosciences Inc
  • Ono Pharmaceutical Co Ltd
  • PharmAkea Therapeutics Inc
  • Ribomic Inc
  • Sansho Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • X-Rx Inc
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles
  • 2-CCPA - Drug Profile
  • BBT-877 - Drug Profile
  • BLD-0409 - Drug Profile
  • GLPG-1690 - Drug Profile
  • IOA-289 - Drug Profile
  • ONO-8430506 - Drug Profile
  • PAT-048 - Drug Profile
  • RBM-006 - Drug Profile
  • Small Molecule to Inhibit ATX and EGFR for Oncology - Drug Profile
  • Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
  • Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile
  • Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile
  • Small Molecules to Inhibit Autotaxin for Lung Cancer - Drug Profile
  • Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile
  • TJC-0265 - Drug Profile
  • TJC-0316 - Drug Profile
  • X-165 - Drug Profile
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Products
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p43fe2

View source version on businesswire.com: https://www.businesswire.com/news/home/20200117005273/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900